<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To identify predictors of antithrombotic treatment in neonates with cerebral sinovenous <z:mp ids='MP_0005048'>thrombosis</z:mp> (CSVT) in a large multinational study </plain></SENT>
<SENT sid="1" pm="."><plain>STUDY DESIGN: Neonates with CSVT from 10 countries were enrolled in the International Pediatric <z:hpo ids='HP_0001297'>Stroke</z:hpo> Study from 2003 through 2007 </plain></SENT>
<SENT sid="2" pm="."><plain>Term neonates with CSVT who presented with neurologic symptoms or signs of <z:e sem="disease" ids="C0442893" disease_type="Disease or Syndrome" abbrv="">systemic illness</z:e> and neuroimaging evidence of <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> or flow interruption within cerebral venous system were included </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: Of 341 neonates enrolled, 84 had isolated CSVT </plain></SENT>
<SENT sid="4" pm="."><plain>Neuroimaging findings, available in 67/84 neonates, included venous ischemic infarction in 5, hemorrhagic infarction or other <z:hpo ids='HP_0002170'>intracranial hemorrhage</z:hpo> in 13, both infarction and <z:mp ids='MP_0001914'>hemorrhage</z:mp> in 26, and no parenchymal lesions in 23 </plain></SENT>
<SENT sid="5" pm="."><plain>Treatment data, available in 81/84 neonates, included antithrombotic medications in 52% (n = 43), comprising <z:chebi fb="5" ids="28304">heparin</z:chebi> (n = 14), low molecular weight <z:chebi fb="5" ids="28304">heparin</z:chebi> (n = 34), <z:chebi fb="8" ids="10033">warfarin</z:chebi> (n = 1), and aspirin (n = 2) </plain></SENT>
<SENT sid="6" pm="."><plain>By univariate logistic regression analysis, deep venous system <z:mp ids='MP_0005048'>thrombosis</z:mp> (P = .05) and location in the United States (P = .001) predicted nontreatment </plain></SENT>
<SENT sid="7" pm="."><plain>Presence of infarction, <z:mp ids='MP_0001914'>hemorrhage</z:mp>, <z:hpo ids='HP_0001944'>dehydration</z:hpo>, <z:e sem="disease" ids="C0442893" disease_type="Disease or Syndrome" abbrv="">systemic illness</z:e>, and age did not predict treatment or nontreatment </plain></SENT>
<SENT sid="8" pm="."><plain>In multivariate analysis only geographic location remained significant </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: In neonatal CSVT, regional antithrombotic treatment practices demonstrate considerable variability and uncertainty about indications for antithrombotic therapy </plain></SENT>
<SENT sid="10" pm="."><plain>Additional studies are warranted </plain></SENT>
</text></document>